BONADUZ, Switzerland, Dec. 16, 2025 /PRNewswire/ — Hamilton today announced the launch of GlucoSense, a breakthrough in bioprocess analytics that introduces theBONADUZ, Switzerland, Dec. 16, 2025 /PRNewswire/ — Hamilton today announced the launch of GlucoSense, a breakthrough in bioprocess analytics that introduces the

Hamilton Launches GlucoSense, a First-of-Its-Kind, Real-Time, In Situ Glucose Sensor for Mammalian Cell Culture

BONADUZ, Switzerland, Dec. 16, 2025 /PRNewswire/ — Hamilton today announced the launch of GlucoSense, a breakthrough in bioprocess analytics that introduces the first reusable, in situ glucose sensor designed to deliver continuous, real-time measurements directly inside cell culture bioreactors. With this release, Hamilton is establishing an entirely new category of process sensors intended to make glucose control as routine and intuitive as measuring pH or dissolved oxygen.

GlucoSense is initially available for wetted autoclave workflows, supporting glass and benchtop bioreactors widely used in R&D and early process development. Hamilton is actively advancing the next phase of product development, and a SIP- and steam-compatible version for steel bioreactors — suitable for clinical and commercial manufacturing — is planned for release by the end of 2026.

“Bioprocessing teams have been asking for a simple, reliable way to measure glucose in situ for years,” said Giovanni Campolongo, Senior Market Segment Manager at Hamilton. “With GlucoSense, we’re giving customers real-time visibility into one of the most critical parameters in mammalian cell culture without the complexity, drift, or calibration burden that has limited previous technologies. And we’ve designed the product roadmap to support every step of the development lifecycle, from R&D to GMP manufacturing.”

A Simple, Robust Solution to a Long-Standing Analytical Gap

Glucose is one of the strongest influencers of cell metabolism, lactate formation, viability, and key quality attributes such as N-linked glycosylation. Yet most bioprocesses still rely on offline or at-line measurements performed once or twice per day, leaving transient glucose drops or spikes undetected. These short-lived events can meaningfully affect product quality, consistency, and overall process robustness.

GlucoSense eliminates this blind spot by providing continuous, in situ measurement using a compact, PG13.5-compatible optical probe engineered specifically for cell culture environments. Unlike Raman and NIR systems that rely on fragile fiber optics, GlucoSense is entirely fiber optic-free, a design choice that enables robust sterilization and supports its compatibility with repeated autoclave cycles. The sensor uses mid-infrared ATR spectroscopy tuned to glucose-specific absorption features, avoiding the chemometric model-building required for spectroscopic platforms. A single-use semi-permeable membrane creates a small measurement chamber that blocks cells and particulates from reaching the diamond ATR element, preventing fouling and delivering stable, drift-resistant data across long cultivation runs.

Each sensor ships with a factory characterization, requiring only a single in situ product calibration at inoculation to account for media background. Integrated Arc intelligent sensor technology stores calibration constants, diagnostics, and quality indicators in the sensor head, enabling seamless digital integration and GMP-ready documentation.

Validated in Partnership with FHNW

Performance data for GlucoSense were generated through Hamilton’s internal development program and through a dedicated collaboration with the University of Applied Sciences and Arts Northwestern Switzerland (FHNW), a globally recognized leader in bioprocess analytics. FHNW ran both fed-batch and perfusion CHO processes to evaluate sensor performance under real culture conditions.

In fed-batch experiments, GlucoSense operated continuously for roughly 130 hours, producing stable, drift-free glucose profiles that closely matched offline reference measurements. In high-density, three-week perfusion runs reaching up to 50 million cells/mL, the sensor delivered consistent real-time glucose values aligned with biomass growth, requiring only weekly product calibrations.

“The validation work with FHNW was essential,” added Campolongo. “Their independent data confirm that GlucoSense performs with the accuracy and stability customers expect and does so without the maintenance, consumables, or spectral modeling that have limited other technologies.”

A Transformative Step Toward Smarter, More Agile Bioprocessing

With GlucoSense, Hamilton is closing one of the last major analytical gaps in upstream processing and laying the foundation for true real-time glucose control across the bioproduction lifecycle. By providing a sensor-based solution that is easy to deploy, stable over time, and scalable across reactor formats, Hamilton is enabling teams to accelerate development, improve product consistency, and prepare their facilities for the increasingly data-driven future of biologics manufacturing.

As the industry advances toward intensified and continuous processing, and as automation, AI-driven optimization, and digital twins become standard, GlucoSense gives manufacturers the continuous nutrient data required to unlock those innovations. Hamilton’s continued development of a SIP-compatible version ensures that the same measurement strategy can span early R&D through large-scale GMP operations, supporting more connected, more robust, and more intelligent bioprocessing worldwide.

About Hamilton:

Hamilton is a leading global manufacturer, providing automated liquid handling workstations, laboratory automation technology, and process analytical sensors to the scientific community. With a focus on innovative design, the Hamilton product portfolio includes liquid handling platforms, standard application-based solutions, small devices, process sensors, consumables, and OEM liquid handling solutions.

Known for advancing the life science, clinical diagnostics, forensics, biotechnology and biopharma industries, Hamilton products offer reliability, performance, and flexibility. Hamilton utilizes state-of-the-art manufacturing at production facilities in Reno, Nevada, and Bonaduz, Switzerland as part of their continuous commitment to quality and has earned a global ISO 9001 certification. Privately held, Hamilton maintains headquarters in Reno, Nevada; Franklin, Massachusetts; and Bonaduz, Switzerland, along with subsidiary offices throughout the world.

Website :
www.hamiltoncompany.com

Media Contact :
Sissy Kephart
1 (775) 858-3000
Sissy.Kephart@hamiltoncompany.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/hamilton-launches-glucosense-a-first-of-its-kind-real-time-in-situ-glucose-sensor-for-mammalian-cell-culture-302642799.html

SOURCE Hamilton Company

Piyasa Fırsatı
RealLink Logosu
RealLink Fiyatı(REAL)
$0.07205
$0.07205$0.07205
-1.61%
USD
RealLink (REAL) Canlı Fiyat Grafiği
Sorumluluk Reddi: Bu sitede yeniden yayınlanan makaleler, halka açık platformlardan alınmıştır ve yalnızca bilgilendirme amaçlıdır. MEXC'nin görüşlerini yansıtmayabilir. Tüm hakları telif sahiplerine aittir. Herhangi bir içeriğin üçüncü taraf haklarını ihlal ettiğini düşünüyorsanız, kaldırılması için lütfen service@support.mexc.com ile iletişime geçin. MEXC, içeriğin doğruluğu, eksiksizliği veya güncelliği konusunda hiçbir garanti vermez ve sağlanan bilgilere dayalı olarak alınan herhangi bir eylemden sorumlu değildir. İçerik, finansal, yasal veya diğer profesyonel tavsiye niteliğinde değildir ve MEXC tarafından bir tavsiye veya onay olarak değerlendirilmemelidir.

Ayrıca Şunları da Beğenebilirsiniz

Ethereum unveils roadmap focusing on scaling, interoperability, and security at Japan Dev Conference

Ethereum unveils roadmap focusing on scaling, interoperability, and security at Japan Dev Conference

The post Ethereum unveils roadmap focusing on scaling, interoperability, and security at Japan Dev Conference appeared on BitcoinEthereumNews.com. Key Takeaways Ethereum’s new roadmap was presented by Vitalik Buterin at the Japan Dev Conference. Short-term priorities include Layer 1 scaling and raising gas limits to enhance transaction throughput. Vitalik Buterin presented Ethereum’s development roadmap at the Japan Dev Conference today, outlining the blockchain platform’s priorities across multiple timeframes. The short-term goals focus on scaling solutions and increasing Layer 1 gas limits to improve transaction capacity. Mid-term objectives target enhanced cross-Layer 2 interoperability and faster network responsiveness to create a more seamless user experience across different scaling solutions. The long-term vision emphasizes building a secure, simple, quantum-resistant, and formally verified minimalist Ethereum network. This approach aims to future-proof the platform against emerging technological threats while maintaining its core functionality. The roadmap presentation comes as Ethereum continues to compete with other blockchain platforms for market share in the smart contract and decentralized application space. Source: https://cryptobriefing.com/ethereum-roadmap-scaling-interoperability-security-japan/
Paylaş
BitcoinEthereumNews2025/09/18 00:25
MMDA, sleep health organization launch drowsy driving campaign ahead of holidays

MMDA, sleep health organization launch drowsy driving campaign ahead of holidays

The Metro Manila Development Authority (MMDA) and the Philippine Society of Sleep Medicine (PSSM) on Wednesday launch an awareness campaign to prevent drowsy driving
Paylaş
Bworldonline2025/12/18 12:05
A Netflix ‘KPop Demon Hunters’ Short Film Has Been Rated For Release

A Netflix ‘KPop Demon Hunters’ Short Film Has Been Rated For Release

The post A Netflix ‘KPop Demon Hunters’ Short Film Has Been Rated For Release appeared on BitcoinEthereumNews.com. KPop Demon Hunters Netflix Everyone has wondered what may be the next step for KPop Demon Hunters as an IP, given its record-breaking success on Netflix. Now, the answer may be something exactly no one predicted. According to a new filing with the MPA, something called Debut: A KPop Demon Hunters Story has been rated PG by the ratings body. It’s listed alongside some other films, and this is obviously something that has not been publicly announced. A short film could be well, very short, a few minutes, and likely no more than ten. Even that might be pushing it. Using say, Pixar shorts as a reference, most are between 4 and 8 minutes. The original movie is an hour and 36 minutes. The “Debut” in the title indicates some sort of flashback, perhaps to when HUNTR/X first arrived on the scene before they blew up. Previously, director Maggie Kang has commented about how there were more backstory components that were supposed to be in the film that were cut, but hinted those could be explored in a sequel. But perhaps some may be put into a short here. I very much doubt those scenes were fully produced and simply cut, but perhaps they were finished up for this short film here. When would Debut: KPop Demon Hunters theoretically arrive? I’m not sure the other films on the list are much help. Dead of Winter is out in less than two weeks. Mother Mary does not have a release date. Ne Zha 2 came out earlier this year. I’ve only seen news stories saying The Perfect Gamble was supposed to come out in Q1 2025, but I’ve seen no evidence that it actually has. KPop Demon Hunters Netflix It could be sooner rather than later as Netflix looks to capitalize…
Paylaş
BitcoinEthereumNews2025/09/18 02:23